(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone
Peritoneal Neoplasm
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Corcept Therapeutics
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06906341CT.gov Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | — | Recruiting | — | — | — |
NCT05257408CT.gov Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone (this asset) | Corcept Therapeutics | P3 | BB · 64 |
| Carboplatin | Eli Lilly and Company | P3 | BBB |
| Adriamycin | Eli Lilly and Company | P3 | BBB |
| Nogitecan | Eli Lilly and Company | P3 | BB |
| Patupilone | Novartis Pharmaceuticals | P3 | BB |
| Oxaliplatin | Sun Yat-sen University | P2/3 | BB |
| Fluorouracilum | AstraZeneca | P2 | BB |
| Olaparib | Merck Sharp & Dohme LLC | P3 | B |
| Pembrolizumab | Seagen, a wholly owned subsidiary of Pfizer | P3 | B |
+36 more in the Peritoneal Neoplasm cohort
Other indications for (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cushing Syndrome | — | P3 | BBB · 72 |
| Pancreatic Ductal Adenocarcinoma | — | P3 | BB · 64 |
| Ovarian Neoplasm | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone in Peritoneal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/r-1-4-fluorophenyl-6-1-methyl-1h-pyrazol-4-ylsulfonyl-145678-hexahydro-4ah-pyrazolo34-gisoquinolin-4a-yl4-trifluoromethylpyridin-2-ylmethanone-peritoneal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →